It has been pointed out that NSCLC metastasizes through the EGFR-PI3K/AKT-FOXA1-PLOD2 pathway, providing a basis for PLOD2 as a therapeutic target for NSCLC treatment63. The gene discussed is PLOD2; the disease is non-small cell lung carcinoma.